相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New Approaches to Chronic Hepatitis B
Geoffrey Dusheiko et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naive patients with chronic hepatitis B
Man-Fung Yuen et al.
LIVER INTERNATIONAL (2023)
Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants
Chang-Ru Wu et al.
HEPATOLOGY (2022)
Getting to HBV cure: The promising paths forward
Scott Fung et al.
HEPATOLOGY (2022)
Letter to the editor: GALAD score: Superior surveillance strategy or not?
Anurag Sachan et al.
HEPATOLOGY (2022)
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Grace L. H. Wong et al.
JOURNAL OF HEPATOLOGY (2022)
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Man-Fung Yuen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression
Srijanee Das et al.
SCIENCE ADVANCES (2022)
Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects
Andrew Vaillant
VIRUSES-BASEL (2022)
Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B
Stephane Daffis et al.
HEPATOLOGY (2021)
Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection
Hannah S. J. Choi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette et al.
CELL (2021)
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators
Oliver E. Amin et al.
HEPATOLOGY (2021)
In Memoriam: Peter J. Meier (1947-2021) Obituary
Bruno Stieger et al.
JOURNAL OF HEPATOLOGY (2021)
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection
Gail V. Matthews et al.
JOURNAL OF HEPATOLOGY (2021)
Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans
Natarajan Ayithan et al.
VIRUSES-BASEL (2021)
Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies
Laura A. Novotny et al.
VIRUSES-BASEL (2021)
Interferon and Hepatitis B: Current and Future Perspectives
Jianyu Ye et al.
FRONTIERS IN IMMUNOLOGY (2021)
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial
Man-Fung Yuen et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
Haiyan Ma et al.
JHEP REPORTS (2021)
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial
Fabien Zoulim et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Man-Fung Yuen et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
Michel Bazinet et al.
GASTROENTEROLOGY (2020)
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Alba Grifoni et al.
CELL (2020)
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim et al.
GASTROENTEROLOGY (2020)
Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection
Valeria Fumagalli et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
Man-Fung Yuen et al.
JOURNAL OF HEPATOLOGY (2020)
Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial
Florian van Bömmel et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data
Harry Janssen et al.
JOURNAL OF HEPATOLOGY (2020)
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients
Alessandro Loglio et al.
JOURNAL OF HEPATOLOGY (2019)
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study
Edward Gane et al.
JOURNAL OF HEPATOLOGY (2019)
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)
Kin Seng Liem et al.
GUT (2019)
Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
Yee Hui Yeo et al.
GASTROENTEROLOGY (2019)
HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues
Terry Cheuk-Fung Yip et al.
JOURNAL OF HEPATOLOGY (2019)
A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B
Safiehkhatoon Moshkani et al.
JOURNAL OF VIROLOGY (2019)
Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B
Wen-Juei Jeng et al.
HEPATOLOGY (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
Harry L. A. Janssen et al.
JOURNAL OF HEPATOLOGY (2018)
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B
Fanny Lebosse et al.
JOURNAL OF HEPATOLOGY (2017)
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2017)
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks
Manasa Suresh et al.
PLOS ONE (2017)
Pharmacotherapeutic options for hepatitis B
Yi-Cheng Chen et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis
Anna S. F. Lok et al.
HEPATOLOGY (2016)
HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant
William S. Mason et al.
GASTROENTEROLOGY (2016)
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
Henry L. Y. Chan et al.
JOURNAL OF HEPATOLOGY (2016)
Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination
Danming Zhu et al.
JOURNAL OF IMMUNOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors
Yadira Lobaina et al.
MOLECULAR IMMUNOLOGY (2015)
Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B
Naoky C. Tsai et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Perrine Martin et al.
GUT (2015)
Treating Immune-tolerant Hepatitis B
T-C Tseng et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
Henry L. Y. Chan et al.
GASTROENTEROLOGY (2014)
Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis
Weixia Ke et al.
PLOS ONE (2014)
Toll-like receptor signaling pathways
Takumi Kawasaki et al.
FRONTIERS IN IMMUNOLOGY (2014)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells
Anna Schurich et al.
PLOS PATHOGENS (2013)
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome
Laura Belloni et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Silencing disease genes in the laboratory and the clinic
Jonathan K. Watts et al.
JOURNAL OF PATHOLOGY (2012)
Three Years of Continuous Entecavir Therapy in Treatment-Naive Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety
Man-Fung Yuen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
E. Jenny Heathcote et al.
GASTROENTEROLOGY (2011)
Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss
Roeland Zoutendijk et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection
Sheikh Mohammad Fazle Akbar et al.
ANTIVIRAL THERAPY (2010)
Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C
Mazen Noureddin et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2010)
The replication cycle of hepatitis B virus
Stephan Urban et al.
JOURNAL OF HEPATOLOGY (2010)
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2009)
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
Daniel Shouval et al.
JOURNAL OF HEPATOLOGY (2009)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects
Jing-He Yan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Dynamics of hepatitis B virus resistance to lamivudine
C Pallier et al.
JOURNAL OF VIROLOGY (2006)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor
PCN Rensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Peginterferon α-2a (40 kDa):: an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B
WGE Cooksley et al.
JOURNAL OF VIRAL HEPATITIS (2003)
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
CL Lai et al.
CLINICAL INFECTIOUS DISEASES (2003)
Different interferons: pharmacology, pharmacokinetics, proposed mechanisms, safety and side effects
P Arnaud
REVUE DE MEDECINE INTERNE (2002)
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
RP Perrillo et al.
HEPATOLOGY (2002)
Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy
E Puchhammer-Stöckl et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
分享论文
